Risk factor
Negligible price volatility
Profitability factor
Greatly overvalued vs peers
About
Dr. Agarwal's Health Care Limited manages a chain of eye hospitals both within India and abroad. The company delivers a comprehensive range of ophthalmic services, including advanced surgical solutions for cataracts like small incision, phacoemulsification, robotic, and glued intraocular lens procedures. It also offers refractive surgeries designed to correct visual errors, thereby lessening or removing the necessity for glasses and contact lenses. Additional surgical specialties include treatments for retinal conditions, corneal transplantation, pinhole pupilloplasty, oculoplasty, and operations for glaucoma and pterygium. Beyond surgical interventions, the company provides professional medical consultations, in-depth diagnostic services for various eye disorders, and non-surgical therapies such as retinal laser treatment and dry eye management. Furthermore, Dr. Agarwal's Health Care Limited sells optical goods, including spectacles, lenses, contact lenses, and frames, as well as a variety of pharmaceutical products for eye care. The company was founded in 2010 and is based in Chennai, India.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Target Price
The average target price of AGARWALEYE.NS is 549 and suggests 6.87% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recom